Figure 4. KIF20A/NUAK1 induce the resistance of CRC resistant cell lines to Oxaliplatin through activating Nrf2 pathway. (A, B) Immunoblots of Nrf2 protein levels in nuclear extracts from HCT116-Or (A) and H716 (B) cells after treatment with oxaliplatin, with and without prior depletion of NUAK1 by HTH-01-015 (10 μmol/L). (C, D) The mRNA levels of GCLC, GCLM and GPX4 were examined by PCR assay to observe whether NUAK1 depletion could affect the intracellular transcriptional activity of Nrf2 in HCT116-Or (C) and H716 (D) cells. The data are presented as the mean ± SD, ***p < 0.001 (versus Oxaliplatin). (E, F) The cell (HCT116-Or (E) and H716 (F)) viability was measured to observe whether 4-Octyl Itaconate would affect the suppression of oxaliplatin on NUAK1-silenced colorectal cancer cells in vitro. The data are presented as the mean ± SD, ***p < 0.001 (versus siNUAK1+Oxaliplatin).